Delivery Order SPE2DB22D2206-SPE2DB25FHZ06
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $7,530.90 to AmerisourceBergen Drug Corp for Orilissa 150 mg tablets (7-count packages) on August 4, 2025, with completion scheduled for August 5, 2025. This firm fixed price delivery order represents a non-competitive set-aside procurement and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor, was selected to supply this specialized...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Orilissa 200 mg tablets (14-count packaging) with a ceiling value of $8,559.49 under a firm fixed-price contract. This non-set-aside award was competitively procured and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- The Defense Logistics Agency awarded a $6,382.34 firm fixed price delivery order to AmerisourceBergen Drug Corp for Orilissa 150 mg tablets (quantity of 7 units) on July 22, 2025, with an ultimate completion date of July 23, 2025. This non-set-aside contract represents a routine pharmaceutical procurement supporting federal medical supply needs. The award was made to AmerisourceBergen's corporate office, with performance occurring at the company's Conshohocken, Pennsylvania location. This...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,290.82, is for the delivery of Orilissa 150 mg tablets. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Orilissa 150 mg tablets in quantities of 7 units, valued at $8,696.28. This firm fixed-price delivery order, which was not set-aside, was awarded on July 23, 2025, with an ultimate completion date of July 24, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract action under...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Orilissa 150 mg tablets. The $11,137.57 contract has a completion date of May 7, 2025 and is not designated as a set-aside. AmerisourceBergen holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which provides a comprehensive global pharmaceutical support vehicle through...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, for the supply of the medication Orilissa (Elagolix) 150 mg tablets. The contract has a ceiling value of $3,418.68 and a completion date of October 16, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for...
- This federal contract award, valued at $4,377.78, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Orilissa 150 mg tablets and has a completion date of December 10, 2024. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 and running through...
- The Defense Logistics Agency awarded a $1,355.10 delivery order to Amerisourcebergen Drug Corporation for the supply of 150 mg Orilissa tablets. Under this firm fixed price contract, Amerisourcebergen will deliver seven bottles of the prescription drug to a facility in Conshohocken, Pennsylvania by July 3, 2023 to support the DLA's medical supply needs. As a top pharmaceutical distributor, Amerisourcebergen routinely fulfills delivery orders under the DLA's Prime Vendor program on behalf of...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp's Corporate Office division. The contract is for the delivery of 4564338594 units of the prescription medication Orilissa 150 mg tablets. The fixed-price contract has a ceiling value of $1,410.52 and a completion date of April 22, 2024. AmerisourceBergen, a major pharmaceutical distribution company, holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FHZ06Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $6,308.10 to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Orilissa 150 mg tablets (7-count packaging). This is a firm fixed-price, non-set-aside contract with a completion date of July 21, 2025, and performance in Conshohocken, Pennsylvania. Orilissa is an endometriosis treatment medication, representing the type of specialized pharmaceutical product that AmerisourceBergen routinely supplies to federal healthcare systems through its extensive portfolio of medical commodities. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a $999,999,999.00 ceiling value through December 2026. This prime vendor contract serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply medications, vaccines, medical devices, and related commodities to support military healthcare programs and other federal agencies including the Defense Health Agency and U.S. Coast Guard. The company's role as a major pharmaceutical distributor positions it as a critical vendor in the federal medical supply chain, with demonstrated capability to fulfill competitively awarded requirements across diverse therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.3k | 7/18/25 |